Gamida Cell   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Jerusalem Israel (1998)

Organization Overview

First Clinical Trial
2007
NCT00444262
First Marketed Drug
2023
omidubicel (Omisirge)
First NDA Approval
2023
omidubicel (Omisirge)
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

GAMIDA | Gamida Cell ltd | Gamida Cell Ltd.

Active Ingredients

Marketed Drugs (1)

omidubicel (Omisirge) (2023 NDA)

Drugs in Phase 3 Trials (4)

allogeneic cord blood (1 trial)

hydroxyethyl starch (voluven) (1 trial)

nicotinamide (4 trials)

omidubicel (Omisirge) (1 trial)

Drugs in Phase 2 Trials (3)

carlecortemcel-l (1 trial)

codeine (Phenergan) (1 trial)

gda-201 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 2)

Fractures, Bone (Phase 3)

Hemoglobinopathies (Phase 2)

Hip Fractures (Phase 3)

Hodgkin Disease (Phase 2)

Leukemia (Phase 3)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Lymphoma (Phase 3)

Myelodysplastic Syndromes (Phase 3)

Neoplasms (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Preleukemia (Phase 3)

Syndrome (Phase 3)

Thalassemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 7